Article
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2017
Afghahi Anosheh, Timms Kirsten M, Vinayak Shaveta, Jensen Kristin C, Kurian Allison W, Carlson Robert W, Chang Pei-Jen, Schackmann Elizabeth, Hartman Anne-Renee, Ford James M, Telli Melinda L
Abstract excerpt
Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. We evaluated this mechanism of resistance in newly diagnosed patients with BRCA1/2-mutant breast cancer with poor response to neoadjuvant platinum-based therapy.Experimental Design:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.